Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models.
Administration, Sublingual
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Disease Models, Animal
Interferon Type I
/ administration & dosage
Leukocytes
/ drug effects
Melanoma, Experimental
/ pathology
Mice, Inbred C57BL
Mice, Transgenic
Neoplasm Transplantation
/ pathology
Neoplasms
/ drug therapy
Salivary Gland Neoplasms
/ pathology
Her-2
NeuT transgenic mice
cisplatin
cyclophosphamide
immune infiltrates
immune response
lymphoma
magnetic resonance imaging
melanoma
multicolor flow cytometry
salivary ductal carcinoma
sublingual delivery
type I interferon
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 04 2021
08 04 2021
Historique:
received:
18
02
2021
revised:
31
03
2021
accepted:
01
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Salivary gland tumors are a heterogeneous group of neoplasms representing less than 10% of all head and neck tumors. Among salivary gland tumors, salivary duct carcinoma (SDC) is a rare, but highly aggressive malignant tumor resembling ductal breast carcinoma. Sublingual treatments are promising for SDC due to the induction of both local and systemic biological effects and to reduced systemic toxicity compared to other administration routes. In the present study, we first established that the sublingual administration of type I IFN (IFN-I) is safe and feasible, and exerts antitumor effects both as monotherapy and in combination with chemotherapy in transplantable tumor models, i.e., B16-OVA melanoma and EG.7-OVA lymphoma. Subsequently, we proved that sublingual IFN-I in combination with cyclophosphamide (CTX) induces a long-lasting reduction of tumor mass in NeuT transgenic mice that spontaneously develop SDC. Most importantly, tumor shrinkage in NeuT transgenic micewas accompanied by the emergence of tumor-specific cellular immune responses both in the blood and in the tumor tissue. Altogether, these results provide evidence that sublingual IFN holds promise in combination with chemotherapy for the treatment of cancer.
Identifiants
pubmed: 33917958
pii: cells10040845
doi: 10.3390/cells10040845
pmc: PMC8068355
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Interferon Type I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Health - Ricerca corrente
ID : 2019
Organisme : Biolingus AG
ID : 2018-2019
Organisme : AIRC
ID : IG 21366 to G.S.
Références
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Histopathology. 2003 Apr;42(4):348-56
pubmed: 12653946
J Transl Med. 2014 May 10;12:122
pubmed: 24886178
Clin Cancer Res. 2009 Oct 1;15(19):6158-66
pubmed: 19773377
Cancer Res. 2011 Feb 1;71(3):768-78
pubmed: 21156650
Anticancer Res. 2013 Jun;33(6):2587-91
pubmed: 23749912
Vaccines (Basel). 2016 Sep 09;4(3):
pubmed: 27618112
J Immunol. 2011 May 1;186(9):5142-50
pubmed: 21441457
Vaccine. 2019 Aug 23;37(36):5364-5370
pubmed: 31331776
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817234
Am J Vet Res. 2005 Jan;66(1):164-76
pubmed: 15691053
J Invest Dermatol. 2017 Jan;137(1):159-169
pubmed: 27623509
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):451-8
pubmed: 17693125
Br J Cancer. 2014 Feb 4;110(3):625-35
pubmed: 24335926
Methods Enzymol. 2020;632:457-477
pubmed: 32000910
J Immunol. 2006 Dec 1;177(11):7626-33
pubmed: 17114432
J Clin Oncol. 2006 Jun 10;24(17):2673-8
pubmed: 16763282
CA Cancer J Clin. 2021 Feb 4;:
pubmed: 33538338
J Interferon Cytokine Res. 1999 Feb;19(2):157-69
pubmed: 10090401
Cancers Head Neck. 2016 Sep 1;1:11
pubmed: 31093341
Sci Rep. 2020 Oct 12;10(1):16988
pubmed: 33046752
Head Neck. 2002 Apr;24(4):406-10
pubmed: 11933184
J Immunol Methods. 2008 Mar 20;332(1-2):170-4
pubmed: 18164026
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
Int J Oncol. 2009 Jul;35(1):139-48
pubmed: 19513561
Cytokine. 2011 Apr;54(1):1-5
pubmed: 21239178
PLoS One. 2014 Mar 05;9(3):e90001
pubmed: 24599269
Proc Soc Exp Biol Med. 1974 Jul;146(3):809-15
pubmed: 4858239
Oncoimmunology. 2017 Apr 20;6(6):e1317420
pubmed: 28680750
Oncotarget. 2016 Sep 13;7(37):59754-59765
pubmed: 27486759
Mucosal Immunol. 2017 Jan;10(1):79-90
pubmed: 27166558
J Oncol. 2019 Sep 24;2019:2592419
pubmed: 31662750
Cancer Chemother Pharmacol. 2020 Dec;86(6):773-782
pubmed: 33074386
J Immunol. 2005 Oct 15;175(8):5043-9
pubmed: 16210607
Oral Oncol. 2019 Jan;88:95-101
pubmed: 30616805
Med Oncol. 2018 Feb 13;35(3):37
pubmed: 29441454
Cancers (Basel). 2020 Oct 24;12(11):
pubmed: 33114321
Front Oncol. 2020 Oct 22;10:580141
pubmed: 33194707
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Curr Protoc Immunol. 2008 Aug;Chapter 20:Unit 20.9.1-20.9-10
pubmed: 18729063
J Clin Diagn Res. 2015 Feb;9(2):ZE04-8
pubmed: 25859537
Clin Exp Allergy. 2015 Mar;45(3):677-86
pubmed: 24773115
Blood. 2005 Apr 1;105(7):2862-8
pubmed: 15591121
Laryngoscope. 2021 May;131(5):E1481-E1488
pubmed: 33022760
J Immunol. 2011 Dec 1;187(11):6130-42
pubmed: 22048768
Vaccine. 2010 Jun 7;28(25):4175-80
pubmed: 20412876
Cancer Immunol Res. 2018 Jun;6(6):658-670
pubmed: 29622580
Cells. 2020 Apr 10;9(4):
pubmed: 32290265
Pathol Res Pract. 2001;197(9):621-6
pubmed: 11569926
Immunol Lett. 1999 Jan;65(1-2):21-5
pubmed: 10065622
Vaccine. 2007 Dec 12;25(51):8598-610
pubmed: 17996991
Semin Immunopathol. 2011 Jul;33(4):369-83
pubmed: 21611872
PLoS Pathog. 2011 Jan 13;7(1):e1001254
pubmed: 21249177
Cancers (Basel). 2019 Oct 26;11(11):
pubmed: 31717819
Mol Cancer. 2021 Feb 4;20(1):27
pubmed: 33541368
J Immunother. 2007 Jan;30(1):40-53
pubmed: 17198082
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11
pubmed: 15629600
Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100-5
pubmed: 4301301
Cytokine Growth Factor Rev. 2015 Apr;26(2):121-31
pubmed: 25578520
J Interferon Cytokine Res. 1999 Feb;19(2):145-55
pubmed: 10090400
NMR Biomed. 2019 Oct;32(10):e4016
pubmed: 30375088
Cancer Treat Rev. 2020 Sep;89:102069
pubmed: 32717621
Int J Cancer. 2000 Nov 1;88(3):329-35
pubmed: 11054659
J Pathol. 1994 Jan;172(1):35-44
pubmed: 7931825
Sci Rep. 2019 Sep 4;9(1):12724
pubmed: 31484986
Hum Pathol. 1996 Jun;27(6):561-6
pubmed: 8666365
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53
pubmed: 17255288
Oncol Rep. 2015 Nov;34(5):2715-21
pubmed: 26329778
Cancer Res. 2007 Aug 1;67(15):7477-86
pubmed: 17671218
Vaccine. 2011 Jun 24;29(29-30):4690-7
pubmed: 21569812
Oral Oncol. 2017 Aug;71:41-46
pubmed: 28688689
Immunotherapy. 2020 Aug;12(12):921-931
pubmed: 32611211
Oral Surg Oral Med Oral Pathol. 1994 Jul;78(1):74-80
pubmed: 7915829
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1644-9
pubmed: 18227512
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Nutrients. 2020 May 14;12(5):
pubmed: 32423101
Int J Cancer. 2018 Mar 1;142(5):976-987
pubmed: 28975621